Lipocine Inc. (LPCN) Fair Value 2026

LPCN · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.1 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (28/100)

Quick Summary — As of 2026-08-28, Lipocine Inc. (LPCN) trades at $2.17. QOC: 6.1/10. Value Trap Risk: 28/100 (LOW). 1/13 models active.

Key Facts

Ticker
LPCN
Price
$2.17
Quality Score
6.1/10
Value Trap Risk
28/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give LPCN?

1 Intrinsic Value Models vs. Current Price ($2.17)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.37 -82.9%

All Models Active

All 1 models are displayed above.

What Is Lipocine Inc. (LPCN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Lipocine Inc.'s intrinsic value is estimated at $0.37, suggesting the stock is overvalued at its current price of $2.17. With 1 out of 1 models flagging downside (-82.9% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About LPCN?

1 of 13 models are currently active for LPCN. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does LPCN Rank in Biotechnology?

Among 625 Biotechnology stocks, LPCN ranks #142 by Quality of Company score. CirclFi's QOC score of 6.1/10 evaluates 32 fundamental signals. A score of 6.1 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Lipocine Inc. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating LPCN should weigh these sector-specific dynamics alongside our model-derived fair values.

Is LPCN a Value Trap?

CirclFi's Value Trap algorithm assigns LPCN a score of 28/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Lipocine Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Lipocine Inc.'s fundamental quality profile registers 6.1/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every LPCN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across LPCN's 1 active models, average confidence is 53%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Lipocine Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

INMBINmune Bio Inc.QOC 6.1VALNValneva SEQOC 6.0TSHATaysha Gene Therapies, Inc.QOC 6.1PRQRProQR Therapeutics N.V.QOC 6.0AARDAardvark Therapeutics, Inc.QOC 6.1ALECAlector, Inc.QOC 6.0SLSSELLAS Life Sciences Group, Inc.QOC 5.1HOWLWerewolf Therapeutics, Inc.QOC 4.5EPRXEupraxia Pharmaceuticals Inc.QOC 2.4EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: INMB · VALN · TSHA · PRQR · AARD · ALEC · SLS · HOWL · EPRX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to LPCN?

7 companies across all industries closest to LPCN’s Quality of Company score of 6.1/10.

ATOMAtomera IncorporatedQOC 6.1CCMConcord Medical Services Holdings LimitedQOC 6.1UCARU Power LimitedQOC 6.1OESXOrion Energy Systems, Inc.QOC 6.1XRAYDENTSPLY SIRONA Inc.QOC 6.1OGIOrganigram Global Inc.QOC 6.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ATOM · CCM · UCAR · OESX · XRAY · OGI · NVDA

Where Does LPCN Sit in CirclFi's Biotechnology Rankings?

LPCN is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Lipocine Inc.’s Valuation?

What is Lipocine Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Lipocine Inc. (LPCN). The Quality of Company score is 6.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is LPCN overvalued or undervalued right now?

At $2.17, 0 of 1 active models suggest LPCN may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Lipocine Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.1 mean for LPCN?

Lipocine Inc.'s QOC of 6.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on LPCN?

CirclFi analyzes LPCN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is LPCN a value trap in 2026?

Lipocine Inc.'s Value Trap score is 28/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Lipocine Inc. (LPCN) a Quality of Company score of 6.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/LPCN/ · Methodology
Primary sources for this LPCN valuation
  • Financial statements: Lipocine Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001535955) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for LPCN as of ; valuations recomputed .